Literature DB >> 15993984

The cAMP-specific phosphodiesterase 4B mediates Abeta-induced microglial activation.

Giovanna Sebastiani1, Céline Morissette, Caroline Lagacé, Marie Boulé, Marie-Josée Ouellette, Richard W McLaughlin, Diane Lacombe, Francine Gervais, Patrick Tremblay.   

Abstract

Microglial activation is a key player in the degenerative process that accompanies the deposition of amyloid-beta (Abeta) peptide into senile plaques in Alzheimer's disease (AD) patients. The goal of this study is to identify novel genes involved in microglial activation in response to Abeta peptide. Prompted by the fact that soluble Abeta(1-42) (sAbeta(1-42))-stimulated primary rat microglia produce more tumor necrosis factor-alpha (TNF-alpha) than fibrillar Abeta(1-42) (fAbeta(1-42))-stimulated microglia, we examined gene expression in these cells following stimulation using cDNA arrays. This analysis confirms the upregulation caused by both sAbeta(1-42) and fAbeta(1-42) of pro-inflammatory molecules such as TNF-alpha, interleukin-1beta and macrophage inflammatory protein-1alpha. In addition, other transcripts not previously described in the context of Abeta-induced microglial activation were identified. The modulation of some of these genes within microglial cells seems to be specific to sAbeta(1-42) as compared to fAbeta(1-42) suggesting that different forms of Abeta may activate distinct pathways during the progression of AD. Importantly, we demonstrate that Pde4B, a cAMP-specific phosphodiesterase, is upregulated by Abeta and results in an increased production of TNF-alpha. Inhibition of Pde4B reduces by up to 70% the release of TNF-alpha from sAbeta-stimulated microglial cells, implicating cAMP as an important mediator of Abeta-induced microglial activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15993984     DOI: 10.1016/j.neurobiolaging.2005.03.024

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  15 in total

1.  beta-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits.

Authors:  Tarja Malm; Michael Ort; Leena Tähtivaara; Niko Jukarainen; Gundars Goldsteins; Jukka Puoliväli; Antti Nurmi; Raimo Pussinen; Toni Ahtoniemi; Taina-Kaisa Miettinen; Katja Kanninen; Suvi Leskinen; Nina Vartiainen; Juha Yrjänheikki; Reino Laatikainen; Marni E Harris-White; Milla Koistinaho; Sally A Frautschy; Jan Bures; Jari Koistinaho
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-24       Impact factor: 11.205

Review 2.  PDE4 as a target for cognition enhancement.

Authors:  Wito Richter; Frank S Menniti; Han-Ting Zhang; Marco Conti
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

Review 3.  Senescent-induced dysregulation of cAMP/CREB signaling and correlations with cognitive decline.

Authors:  Rolf T Hansen; Han-Ting Zhang
Journal:  Brain Res       Date:  2013-04-25       Impact factor: 3.252

4.  Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain.

Authors:  Amanda Ellis; Julie Wieseler; Jacob Favret; Kirk W Johnson; Kenner C Rice; Steven F Maier; Scott Falci; Linda R Watkins
Journal:  J Pain       Date:  2014-01-09       Impact factor: 5.820

Review 5.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

6.  Following spinal cord injury, PDE4B drives an acute, local inflammatory response and a chronic, systemic response exacerbated by gut dysbiosis and endotoxemia.

Authors:  Scott A Myers; Leila Gobejishvili; Sujata Saraswat Ohri; C Garrett Wilson; Kariena R Andres; Amberly S Riegler; Hridgandh Donde; Swati Joshi-Barve; Shirish Barve; Scott R Whittemore
Journal:  Neurobiol Dis       Date:  2018-12-14       Impact factor: 5.996

Review 7.  Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.

Authors:  Mark E Gurney; Emily C D'Amato; Alex B Burgin
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

8.  The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release.

Authors:  Sondra T Bland; Mark R Hutchinson; Steven F Maier; Linda R Watkins; Kirk W Johnson
Journal:  Brain Behav Immun       Date:  2009-02-03       Impact factor: 7.217

9.  Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury.

Authors:  Mousumi Ghosh; Daniela Garcia-Castillo; Vladimir Aguirre; Roozbeh Golshani; Coleen M Atkins; Helen M Bramlett; W Dalton Dietrich; Damien D Pearse
Journal:  Glia       Date:  2012-08-02       Impact factor: 7.452

10.  The biphasic role of microglia in Alzheimer's disease.

Authors:  Tetsuya Mizuno
Journal:  Int J Alzheimers Dis       Date:  2012-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.